Immunotoxin

The founder of Department of Tumor Biology, Prof Øystein Fodstad, brought together key technologies to develop immunotoxins comprising full-length murine antibodies against surface antigens that are overexpressed in cancer coupled to Pseudomonas exotoxin A (PE). The two most promising drug candidates have been MOC31PE and BM7PE, targeting EpCAM and Muc1, respectively. In a series of research projects, these immunotoxins have been explored preclinically and in clinical trials. Preclinically, these drugs have exhibited remarkable ability to kill tumor cells, with negligible off-target activity. In clinical trials (metastatic colorectal cancer), MOC31PE was shown to be well tolerated when administered intravenously or intraperitoneally, with interesting long-term results and importantly, immune activation.  

We are currently conducting a phase 1 trial of BM7PE in patients with end-stage metastatic colorectal cancer https://clinicaltrials.gov/.

Previously published articles:

Thorgersen EB et. al. 2021

Andersson Y et. al. 2020

Frøysnes I et.al. 2019

Andersson Y et.al 2017

Frøysnes I et.al. 2017

Andersson Y et.al 2015

Wiiger MT et.al 2014

Flatmark K et.al 2013

Engebraaten O et.al 2000

 

Illustration of the MOC31PE immunotoxin, its internalization and mode of action. MOC31PE is composed of the MOC31 monoclonal antibody targeting the tumor-associated antigen EpCAM, covalently linked to Pseudomonas exotoxin A (PE). The antibody directs the MOC31PE to EpCAM-expressing cancer cells, and when internalized, the toxin effector moiety rapidly triggers cell death by catalytic inactivation of vital processes, and by directly inducing apoptosis.

 
Page visits: 215